[HTML][HTML] Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung …
N Heersche, GDM Veerman, M de With, S Bins… - Drug Resistance …, 2022 - Elsevier
Small-molecule kinase inhibitors (SMKIs) represent the cornerstone in the treatment of non-
small cell lung cancer (NSCLC) patients harboring genetic driver mutations. Because of the …
small cell lung cancer (NSCLC) patients harboring genetic driver mutations. Because of the …
FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
S Guan, X Chen, Y Chen, W Xie, H Liang, X Zhu… - Clinical Cancer …, 2022 - AACR
Purpose: Although gefitinib prolonged the progression-free survival (PFS) of patients with
non–small cell lung cancer (NSCLC), unpredictable resistance limited its clinical efficacy …
non–small cell lung cancer (NSCLC), unpredictable resistance limited its clinical efficacy …
[HTML][HTML] Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
C Xu, L Zhang, D Wang, S Jiang, D Cao, Z Zhao… - Cell death …, 2021 - nature.com
Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly
benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired …
benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired …
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
S Guan, X Chen, Y Wei, F Wang, W Xie, Y Chen… - Clinical Cancer …, 2024 - AACR
Purpose: Although somatic mutations were explored in depth, limited biomarkers were found
to predict the resistance of EGFR tyrosine kinase inhibitors (EGFR-TKI). Previous studies …
to predict the resistance of EGFR tyrosine kinase inhibitors (EGFR-TKI). Previous studies …
The pharmacokinetics of gefitinib in a Chinese cancer population group: a virtual clinical trials population study
H Yu, RKS Badhan - Journal of Pharmaceutical Sciences, 2021 - Elsevier
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
[HTML][HTML] A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
T Fukuhara, K Imai, T Nakagawa, R Igusa, H Yokota… - Biomedicines, 2023 - mdpi.com
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung
carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib …
carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib …
[HTML][HTML] The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report
J Zang, H Horinouchi, J Hanaoka, K Funai… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Studies have revealed that the epidermal growth factor receptor (EGFR) mutation is one of
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …
[HTML][HTML] Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of …
S Guan, X Chen, S Xin, S Liu, Y Yang, W Fang… - Translational …, 2021 - Elsevier
Background Rash is a well-known predictor of survival for patients with gefitinib therapy with
non-small cell lung cancer (NSCLC). However, whether patients with more severe rash …
non-small cell lung cancer (NSCLC). However, whether patients with more severe rash …
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug …
Y Ma, Q Chen, Y Zhang, J Xue, Q Liu, Y Zhao… - Cancer Chemotherapy …, 2023 - Springer
Purpose Apatinib combined with gefitinib was proven to benefit advanced EGFR-mutant
NSCLC patients in first-line treatment. This study aimed to evaluate the drug-drug interaction …
NSCLC patients in first-line treatment. This study aimed to evaluate the drug-drug interaction …
[HTML][HTML] Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report
W Du, Y Zhao, Y Xuan, Y Qin, R Xu… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Gefitinib, the first-generation epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non …
(EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non …